Exploring the role of arginase-1 as a potential therapeutic target in the treatment of myeloma and in reducing the cardiotoxicity of proteasome inhibitors

The aim of the planned research is therefore to check whether Arg-1 actually plays a role in the inhibition of an effective immune response and thus in the progression of myeloma. In our research, we will use genetically modified strains of mice, including animals lacking the Arg-1 gene and strains of transgenic mice, which will allow us to study a specific immune response. We will examine whether the lack of Arg-1 or pharmacological inhibition of this enzyme activity affects the progression of myeloma and the development of the immune response. We will also investigate whether an Arg-1 inhibitor may enhance the anti-tumor effects of bortezomib and reduce its cardiotoxicity in animals. The knowledge gained from this research will provide a better understanding of the molecular mechanisms involved in the development of myeloma, the anti-cancer immune response and the side effects of drugs used in oncology. We hope that the research results will also enable the identification of new research areas that can be used in the development of immunology, cardiooncology and experimental oncology.